DsbA  Monoclonal Antibody

P0AEG4  periplasmic protein disulfide isomerase I(dsbA) Escherichia coli str. K-12 substr. MG1655       function:Required for disulfide bond formation in some periplasmic proteins such as phoA or ompA. Acts by transferring its disulfide bond to other proteins and is reduced in the process. DsbA is reoxidized by dsbB. It is required for pilus biogenesis.,similarity:Belongs to the thioredoxin family. DsbA subfamily.,similarity:Contains 1 thioredoxin domain.

Introducing the DSBA Monoclonal Antibody, a cutting-edge biotechnological product designed to revolutionize the field of immunotherapy. This meticulously engineered antibody showcases unparalleled specificity and affinity, rendering it an indispensable tool for researchers and clinicians alike.

The DSBA Monoclonal Antibody is derived from a single clone of hybridoma cells, ensuring a homogeneous population of antibodies with identical antigen-binding properties. This exceptional uniformity guarantees reproducibility and reliability in experimental settings, enabling accurate and consistent results.

With its remarkable binding affinity, the DSBA Monoclonal Antibody exhibits an exceptional ability to recognize and bind to its target antigen with unparalleled precision. This attribute not only enhances the sensitivity of diagnostic assays but also facilitates the isolation and purification of specific antigens, thereby expediting downstream applications.

Furthermore, the DSBA Monoclonal Antibody's exceptional specificity ensures minimal cross-reactivity with non-target molecules, minimizing false-positive results and enhancing the accuracy of diagnostic tests. This attribute is particularly advantageous in clinical settings, where precise and reliable identification of disease markers is of paramount importance.

The DSBA Monoclonal Antibody's versatility extends beyond research and diagnostics, as it also holds immense potential in therapeutic applications. Its ability to selectively bind to disease-specific antigens opens up avenues for targeted drug delivery, thereby minimizing off-target effects and maximizing therapeutic efficacy.

In addition to its exceptional performance, the DSBA Monoclonal Antibody is manufactured under stringent quality control measures, adhering to the highest industry standards. This ensures the utmost purity, stability, and consistency of the product, guaranteeing its suitability for a wide range of applications.

In conclusion, the DSBA Monoclonal Antibody represents a groundbreaking advancement in the field of immunotherapy. Its unrivaled specificity, affinity, and reliability make it an indispensable tool for researchers, clinicians, and pharmaceutical companies alike. Embrace the future of biotechnology with the DSBA Monoclonal Antibody and unlock new possibilities in diagnostics, therapeutics, and beyond.